Diabetic Nephropathy - Prevalence and Therapeutic Potential

Questions: Discounts, Updates etc.

Price: $1,900.00

Publication Date: 2003-10-04

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The diabetic microvascular complication, nephropathy, is a condition with high unmet therapeutic needs. It is linked with significant increases in morbidity and mortality risk, and is the most common cause of ESRD in the US and Europe. Despite the efforts to address the increasing incidence of both type 1 and type 2 diabetes, the diabetic population is set to increase by 72% between 2003 and 2025. Access new data from Datamonitor's 380 physician sample survey on the prevalence and progression of diabetic nephropathy in seven major markets. Understand the views of diabetologist and nephrology opinion leaders on the potential for prescribing ACE inhibitors combined with ARBs in diabetes.

Table of Contents

Other users found this report page using the following search terms: neuropathic pain neuropathy dnp diabetic neuropathy nephropathy diabetic prevalence diabetes ace treatment type vivaldi candesartan telmisartan

If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.